MIT Sloan Health Systems Initiative (HSI) Seminar with Delfi Krishna

When does investing in cell and gene therapy make good business sense?
Thursday April 13, 2023
11:30am - 1pm 
E62-450
Signup at Sloan Groups
In person lunch will be provided 

Join Zoom Meeting
Password: 100
One tap mobile
+16465588656,,93963234492
 
Meeting ID: 939 6323 4492

Cell and gene therapies represent an exciting and complex new treatment type, with the potential to treat a vast range of indications, in some cases offering the possibility of a disease cure with a single treatment. This presentation will discuss the multi-disciplinary business environment required to bring these cutting-edge medicines to patients.  
 
Delfi Krishna is currently the Vice President of Cell Therapy Portfolio Development at Immatics – a German biotech company with the mission to bring the power of T-cells to cancer patients.  She has a Ph.D in Chemical and Biomolecular Engineering from Georgia Tech and is currently an Executive MBA student at MIT Sloan.